CompletedInterventionalPhase 4Last updated Aug 24, 2016

A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

NCT01066884

Overview

ClinicalTrials.gov ID: NCT01066884
Lead Sponsor: Hoffmann-La RocheINDUSTRY
Brief Summary: This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Study Type

Status

Overall Status: Completed
Start Date: Apr 2009
Primary Completion Date: Nov 2009Actual
Completion Date: Nov 2009Actual

Study Record Dates

First Submitted: Feb 4, 2010
First Submitted that Met QC Criteria: Feb 9, 2010
First Posted: Feb 10, 2010Estimated
Last Update Submitted that Met QC Criteria: Aug 22, 2016
Last Update Posted: Aug 24, 2016Estimated
Last Verified: Aug 2016

NCT01609543Completed

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

NCT01996332Completed

A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT01310036Completed

A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

NCT00701558Completed

A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer

NCT01372384Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

NCT00949910Completed

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)